JP2022532790A - 固体形態 - Google Patents

固体形態 Download PDF

Info

Publication number
JP2022532790A
JP2022532790A JP2021568766A JP2021568766A JP2022532790A JP 2022532790 A JP2022532790 A JP 2022532790A JP 2021568766 A JP2021568766 A JP 2021568766A JP 2021568766 A JP2021568766 A JP 2021568766A JP 2022532790 A JP2022532790 A JP 2022532790A
Authority
JP
Japan
Prior art keywords
present disclosure
ray
compound
powder
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532790A5 (enExample
Inventor
チャベス，メアリー
ケリー，ロン・シー
アガルワル，パラシェント
ペアレント，スティーブン・ディー
リード，ダーレン・レナード
シマノビッチ，ロマン
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2022532790A publication Critical patent/JP2022532790A/ja
Publication of JP2022532790A5 publication Critical patent/JP2022532790A5/ja
Priority to JP2025080319A priority Critical patent/JP2025131597A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
JP2021568766A 2019-05-21 2020-05-20 固体形態 Pending JP2022532790A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080319A JP2025131597A (ja) 2019-05-21 2025-05-13 固体形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851049P 2019-05-21 2019-05-21
US62/851,049 2019-05-21
PCT/US2020/033832 WO2020236948A1 (en) 2019-05-21 2020-05-20 Solid state forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080319A Division JP2025131597A (ja) 2019-05-21 2025-05-13 固体形態

Publications (2)

Publication Number Publication Date
JP2022532790A true JP2022532790A (ja) 2022-07-19
JP2022532790A5 JP2022532790A5 (enExample) 2023-05-24

Family

ID=71016701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568766A Pending JP2022532790A (ja) 2019-05-21 2020-05-20 固体形態
JP2025080319A Pending JP2025131597A (ja) 2019-05-21 2025-05-13 固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080319A Pending JP2025131597A (ja) 2019-05-21 2025-05-13 固体形態

Country Status (10)

Country Link
US (1) US12252486B2 (enExample)
EP (1) EP3972972A1 (enExample)
JP (2) JP2022532790A (enExample)
AR (1) AR119741A1 (enExample)
AU (2) AU2020277398B2 (enExample)
CA (1) CA3140394A1 (enExample)
MX (2) MX2021014235A (enExample)
TW (1) TW202110836A (enExample)
UY (1) UY38711A (enExample)
WO (1) WO2020236948A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110366550A (zh) 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
AU2018273356B2 (en) 2017-05-22 2021-09-16 Amgen Inc. KRAS G12C inhibitors and methods of using the same
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
EP3788053B1 (en) 2018-05-04 2024-07-10 Amgen Inc. Kras g12c inhibitors and methods of using the same
CA3098574A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
MA52564A (fr) 2018-05-10 2021-03-17 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
US11096939B2 (en) 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2019384118B2 (en) 2018-11-19 2025-06-12 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
AU2020277398B2 (en) 2019-05-21 2026-01-29 Amgen Inc. Solid state forms
WO2020236947A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
EP4153588A1 (en) * 2020-05-20 2023-03-29 Teva Pharmaceuticals International GmbH Solid state forms of amg-510 and process for preparation thereof
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4253376B1 (en) * 2020-11-26 2025-07-30 Shanghai Hansoh Biomedical Co., Ltd. Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
JP2024518845A (ja) * 2021-05-19 2024-05-07 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー ソトラシブ及びその固体状態形態の調製のためのプロセス
CN114605406B (zh) * 2021-09-18 2023-05-26 都创(上海)医药开发有限公司 Amg510化合物的晶型及其制备方法和用途
CN115368358A (zh) * 2022-09-01 2022-11-22 浙江九洲药业股份有限公司 一种Sotorasib新晶型及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031476A (ja) * 2017-05-22 2019-02-28 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
WO2019051291A1 (en) * 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312059D0 (en) 2013-07-05 2013-08-21 Univ Leuven Kath Novel GAK modulators
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
EP3055290B1 (en) 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
KR102444509B1 (ko) 2016-05-18 2022-09-19 미라티 테라퓨틱스, 인크. Kras g12c 억제제
CN110366550A (zh) 2016-12-22 2019-10-22 美国安进公司 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
CA3098574A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020236947A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
AU2020277398B2 (en) 2019-05-21 2026-01-29 Amgen Inc. Solid state forms
JP7837865B2 (ja) 2019-11-14 2026-03-31 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改良合成法
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019031476A (ja) * 2017-05-22 2019-02-28 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
WO2019051291A1 (en) * 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ｃ．Ｇ．ＷＥＲＭＵＴＨ編, 最新 創薬化学 下巻, JPN6014029314, 1999, pages 347 - 365, ISSN: 0005304981 *
STAHLY，P.: "医薬品の塩選択,結晶多形のスクリーニングの重要性について", 薬剤学, vol. 66, no. 6, JPN6015024142, 2006, pages 435 - 439, ISSN: 0005304982 *
ファルマシア, vol. 52, no. 5, JPN6023009635, 2016, pages 387 - 391, ISSN: 0005662833 *
川口洋子ら: "医薬品と結晶多形", 生活工学研究, JPN6014015069, 2002, pages 310 - 317, ISSN: 0005304983 *
薬剤学, vol. 73, no. 3, JPN6023009633, 2013, pages 176 - 182, ISSN: 0005662834 *

Also Published As

Publication number Publication date
MX2025010774A (es) 2025-10-01
JP2025131597A (ja) 2025-09-09
TW202110836A (zh) 2021-03-16
UY38711A (es) 2020-11-30
AR119741A1 (es) 2022-01-05
MX2021014235A (es) 2022-03-11
AU2020277398A1 (en) 2021-12-09
US20220235045A1 (en) 2022-07-28
AU2020277398B2 (en) 2026-01-29
EP3972972A1 (en) 2022-03-30
US12252486B2 (en) 2025-03-18
AU2026200455A1 (en) 2026-02-12
WO2020236948A1 (en) 2020-11-26
CA3140394A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
JP2022532790A (ja) 固体形態
JP7092935B2 (ja) 固体形態
TWI698428B (zh) Mdm2抑制劑之製備方法及結晶型
WO2022240886A1 (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
HK40116757A (zh) 固态形式
HK40063209A (en) Solid state forms
HK40063209B (zh) 固态形式
EA047965B1 (ru) Твердые формы
EA052301B1 (ru) Твердые формы
BR122024008690A2 (pt) Compostos de formas amorfas, composição farmacêutica comprendendo os mesmos e uso destes para tratamento de câncer com uma mutação kras g12c

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250513